2024 ASCO® Annual Meeting Insights Hub

Forgot your password?

Select specialty

Choose Password

About Us
Careers
Partner with us
F.A.Q
Contact us
Terms & conditions
Privacy policy

Meeting coverage & Vumedi’s exclusive highlights, all in one place.

Summaries & Highlights
Breast
GU
GI
Lung
Hematologic Oncology
Skin
GYN
Head & Neck
Sarcoma

Playback speed

June 13, 2024

Feat. K. Jhaveri

2024 ASCO® Annual Meeting Insights Hub

E. Felip, A. Spira, A. Passaro, A. Addeo

2024 ASCO® Annual Meeting Insights Hub

2024 ASCO® Annual Meeting Insights Hub

2024 ASCO® Annual Meeting Insights Hub

2024 ASCO® Annual Meeting Insights Hub

2024 ASCO® Annual Meeting Insights Hub

2024 ASCO® Annual Meeting Insights Hub

M. Marmarelis

2024 ASCO® Annual Meeting Insights Hub

2024 ASCO® Annual Meeting Insights Hub

S. Ramalingam

2024 ASCO® Annual Meeting Insights Hub

2024 ASCO® Annual Meeting Insights Hub

2024 ASCO® Annual Meeting Insights Hub

2024 ASCO® Annual Meeting Insights Hub

2024 ASCO® Annual Meeting Insights Hub

2024 ASCO® Annual Meeting Insights Hub

2024 ASCO® Annual Meeting Insights Hub

2024 ASCO® Annual Meeting Insights Hub

2024 ASCO® Annual Meeting Insights Hub

2024 ASCO® Annual Meeting Insights Hub

2024 ASCO® Annual Meeting Insights Hub

2024 ASCO® Annual Meeting Insights Hub

Login

Login

Join VuMedi

2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Insights: "NRG-LU002 Trial - Maintenance Systemic Therapy +/- Local Consolidative Therapy in Limited mNSCLC"

NRG-LU002 Trial Overview & Key Takeaways

Historical Context & Trial Rationale

Trial Design & Patient Stratification

Primary Objectives & Radiation Schema

PFS, OS Rates & Toxicity Findings

Study Limitations & Concluding Remarks

Resistance Mechanisms to ET, Including ESR1 Mutations in HR+, HER2- …

Treatment Decisions When Initiating a Tyrosine Kinase Inhibitor and …

ASCO® 2024 Summary: "SCLC Treatment Evolution - Debunking Myths, IO …

ASCO® 2024: Highlights and Analysis of Key Solid Cancer Trials

ASCO® 2024 Insights: "NRG-LU002 Trial - Maintenance vs. Local Consol…

ASCO® 2024 Lung Cancer Updates: CROWN, ADRIATIC, and LAURA Trials

ASCO® 2024 Insights: "HARMONi-A Study - Ivonescimab + Chemo for EGFR…

ASCO® 2024 Lung Cancer Roundtable: Advances in NSCLC

ASCO® 2024 Lung Cancer Highlights: CROWN, LAURA, ADRIATIC, and PALOM…

ASCO® 2024 Lung Cancer Highlights: Top Abstracts Including BEAT-SC, …

ASCO® 2024 Insights: "KRYSTAL-12 Study - Adagrasib vs. Docetaxel in …

ASCO® 2024 Insights: "RAGNAR Trial - Erdafitinib Efficacy & Safety i…

ASCO® 2024 Insights: "SAVE Study - Comparing Suspension vs. Continua…

ASCO® 2024 Summary: "BEAT Trials and Neoadjuvant Strategies - Advanc…

ASCO® 2024 Precision Medicine Highlights: LAURA and CROWN Trials (NS…

ASCO® 2024 Insights: "ADRIATIC Study - Durvalumab as Consolidation T…

ASCO® 2024 Insights: "TROPION-Lung05 Study - Intracranial Efficacy o…

ASCO® 2024 Insights: "LAURA Study - Osimertinib After Definitive CRT…

ASCO® 2024 Insights: "Telehealth Palliative Care for Advanced Lung C…

ASCO® 2024 Insights: "HARMONi-A Trial - Ivonescimab Combined With Ch…

ASCO® 2024 Insights: "ETOP 13-18 BEAT-meso Trial - Bevacizumab + Che…

ASCO® 2024 Insights: "LIBRETTO-432 Trial - Adjuvant Selpercatinib vs…

ASCO® 2024 Insights: "KRYSTAL-12 Study - Adagrasib vs. Docetaxel in …

ASCO® 2024 Insights: "CHRYSALIS-2 Trial - Amivantamab + Lazertinib i…

ASCO® 2024 Insights: "Assessing Secular Trends in Lung Cancer Stage …

ASCO® 2024 Insights: "NRG-LU002 Trial - Maintenance Systemic Therapy…

ASCO® 2024 Insights: "Impact on Biomarker Documentation in Community…

ASCO® 2024 Insights: "Evolution Trial - RT-Free Pembro + Chemo in Hi…

ASCO® 2024 Insights: "MIST5 Trial - Niraparib & Dostarlimab in Plati…

ASCO® 2024 Insights: "Multi-Center Phase II Trial Investigating Safe…

ASCO® 2024 Insights: "PALOMA-2 Study - Subcutaneous Amivantamab & La…

ASCO® 2024 Insights: "First-in-Human Trial of RSO-021 in Malignant P…